CN113397170A - 一种用于调节人体肠道菌群的海洋益生元组合物及其应用 - Google Patents
一种用于调节人体肠道菌群的海洋益生元组合物及其应用 Download PDFInfo
- Publication number
- CN113397170A CN113397170A CN202110617542.3A CN202110617542A CN113397170A CN 113397170 A CN113397170 A CN 113397170A CN 202110617542 A CN202110617542 A CN 202110617542A CN 113397170 A CN113397170 A CN 113397170A
- Authority
- CN
- China
- Prior art keywords
- marine
- oligosaccharide
- prebiotic composition
- mass ratio
- seaweed polyphenol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 68
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 30
- 230000001105 regulatory effect Effects 0.000 title abstract description 11
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 60
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 60
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 29
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 28
- 241001474374 Blennius Species 0.000 claims abstract description 26
- 235000021391 short chain fatty acids Nutrition 0.000 claims abstract description 18
- 239000006041 probiotic Substances 0.000 claims abstract description 17
- 235000018291 probiotics Nutrition 0.000 claims abstract description 17
- 150000004666 short chain fatty acids Chemical class 0.000 claims abstract description 13
- 230000035755 proliferation Effects 0.000 claims abstract description 12
- 230000000813 microbial effect Effects 0.000 claims abstract description 9
- 230000001737 promoting effect Effects 0.000 claims abstract description 9
- 230000036541 health Effects 0.000 claims abstract description 8
- 230000003871 intestinal function Effects 0.000 claims abstract description 8
- 230000004151 fermentation Effects 0.000 claims abstract description 7
- 238000000855 fermentation Methods 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 241000206572 Rhodophyta Species 0.000 claims description 14
- 241000199919 Phaeophyceae Species 0.000 claims description 13
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 10
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 10
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 10
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 6
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 235000011054 acetic acid Nutrition 0.000 claims description 5
- 235000019260 propionic acid Nutrition 0.000 claims description 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 5
- 229940005605 valeric acid Drugs 0.000 claims description 5
- 241000605947 Roseburia Species 0.000 claims description 4
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 claims description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 claims description 3
- 241000195649 Chlorella <Chlorellales> Species 0.000 claims description 3
- 241000195628 Chlorophyta Species 0.000 claims description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- -1 polyphenol compound Chemical class 0.000 claims description 3
- 230000000529 probiotic effect Effects 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 244000039328 opportunistic pathogen Species 0.000 claims 2
- 241000194036 Lactococcus Species 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000001143 conditioned effect Effects 0.000 abstract description 2
- 244000052769 pathogen Species 0.000 abstract description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 14
- 244000052616 bacterial pathogen Species 0.000 description 9
- 230000034659 glycolysis Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 244000057717 Streptococcus lactis Species 0.000 description 5
- 235000014897 Streptococcus lactis Nutrition 0.000 description 5
- 241000186012 Bifidobacterium breve Species 0.000 description 4
- 241001608472 Bifidobacterium longum Species 0.000 description 4
- 241000589989 Helicobacter Species 0.000 description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 4
- 229940009291 bifidobacterium longum Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241001134770 Bifidobacterium animalis Species 0.000 description 3
- 241000186016 Bifidobacterium bifidum Species 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 241000605716 Desulfovibrio Species 0.000 description 3
- 241000194033 Enterococcus Species 0.000 description 3
- 241001134659 Lactobacillus curvatus Species 0.000 description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940118852 bifidobacterium animalis Drugs 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- 241000186869 Lactobacillus salivarius Species 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000015816 nutrient absorption Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000004153 Hibiscus sabdariffa Species 0.000 description 1
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 241000598080 Occia Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000007671 pyg medium Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种用于调节人体肠道菌群的海洋益生元组合物及其应用。所述海洋益生元组合物包括海洋低聚糖和海藻多酚作为有效活性成分,所述海洋低聚糖和海藻多酚的质量比为3:1~9:1。经实验验证,所述海洋益生元组合物能够通过有效促进益生菌的增殖以及抑制条件致病菌,达到调节人体肠道菌群,改善肠道功能的作用,并且还能够促进微生物发酵产生多种有益于人体健康的短链脂肪酸SCFAs,促进并维持人体健康。所述海洋益生元组合物用量小,且作用效果佳,还具有原料来源丰富、结构特异、成本低、制备简单方便的优势,因此具有广泛的市场前景。
Description
技术领域
本发明属于益生元制备技术领域,具体涉及一种用于调节人体肠道菌群的海洋益生元组合物及其应用。
背景技术
益生元是指能选择性刺激一种或几种细菌在宿主肠道内生长或活化,增进宿主健康而又不被宿主胃肠道消化的物质。补充益生元可以促进肠道内益生菌增殖,改善肠道菌群结构。深入研究表明,单一的益生元对益生菌的促进作用不具有广谱性,如低聚木糖能促进青春双歧杆菌、长双歧杆菌和唾液乳杆菌增殖,对干酪乳杆菌、发酵乳杆菌、短双歧杆菌、婴儿双歧杆菌和两歧双歧杆菌无明显影响;低聚果糖能促进嗜酸乳杆菌、唾液乳杆菌和多数的双歧杆菌增殖,对两歧双歧杆菌、干酪乳杆菌和发酵乳杆菌促进效果有限;甲壳低聚糖能促进双歧杆菌增殖,对乳杆菌数量无明显影响。而肠道微生态是有种类繁多、数量庞大的微生物组成的复杂群体,单一菌群或少数菌群的增殖对肠道菌群结构的改善较为有限。因此,根据单一益生元的性质进行科学的组合配伍,立足促进多菌群生长,带动肠道菌群结构整体性改善,成为今后益生元应用与产品开发的主要方向。
益生元物质广泛存在于自然界中。功能性低聚糖已成为益生元物质中主要的一类。以往作为益生元物质的功能性低聚糖主要为低聚果糖、菊粉、低聚半乳糖和大豆低聚糖等陆源低聚糖。随着海洋生物资源的深入开发,海洋低聚糖因其具有陆源益生元无可比拟的特殊结构和功能,而成为新型益生元开发新资源。从现有海洋益生元研究来看,单一的海洋益生元同样不具有广谱性作用。并且,海洋益生元组合物对肠道菌群更深层次的调节研究,特别是多菌群调节研究相对较少。因此,开发原料丰富、效果更显著的海洋益生元组合物对促进人体及动物的肠道菌群健康具有重要的意义,也为人体和动物体使用海洋益生元提供更宽的市场选择。
发明内容
本发明的目的是提供一种用于调节人体肠道菌群的海洋益生元组合物及其应用。所述海洋益生元组合物原料丰富、成本低廉、效果明显,具有多菌群调节效果,可以满足多样化的市场需求。
为实现上述发明目的,本发明的技术方案如下:
本发明提供一种用于调节人体肠道菌群的海洋益生元组合物,包括海洋低聚糖和海藻多酚作为有效活性成分,所述海洋低聚糖和海藻多酚的质量比为3∶1~9∶1。
进一步的,所述海洋低聚糖包括褐藻低聚糖、红藻低聚糖、绿藻低聚糖和甲壳低聚糖中的至少一种。
进一步的,所述海洋低聚糖的纯度在50%以上。
进一步的,所述海洋益生元组合物具有下列组成之一:
(1)由褐藻低聚糖、红藻低聚糖和海藻多酚以4∶5∶1的质量比组成;
(2)由红藻低聚糖、甲壳低聚糖和海藻多酚以9∶9∶2的质量比组成;
(3)由褐藻低聚糖、红藻低聚糖、甲壳低聚糖和海藻多酚以14∶21∶10∶5的质量比组成;
(4)由褐藻低聚糖和海藻多酚以4∶1的质量比组成;
(5)由红藻低聚糖和海藻多酚以3∶1的质量比组成;
(6)由绿藻低聚糖和海藻多酚以39∶11的质量比组成。
优选的,所述海洋益生元组合物由褐藻低聚糖、红藻低聚糖、甲壳低聚糖和海藻多酚以14∶21∶10∶5的质量比组成。
本发明还提供了所述的海洋益生元组合物在制备用于调节人体肠道菌群和/或改善肠道功能的食品、保健品或药物制剂中的应用。
进一步的,所述海洋益生元组合物能够通过有效促进益生菌的增殖以及抑制条件致病菌,达到调节人体肠道菌群和/或改善肠道功能的作用。
进一步的,所述益生菌包括罗斯氏菌Roseburia cecicola、鼠李糖乳杆菌Lactobacillus rhamnosus、嗜酸乳杆菌Lactobacillus acidophilus、弯曲乳酸杆菌Lactobacillus curvatus、动物双歧杆菌Bifidobacterium animalis、短双歧杆菌Bifidobacterium breve、长双歧杆菌Bifidobacterium longum和乳酸乳球菌Lactococcuslactis。
进一步的,所述条件致病菌包括脱硫弧菌属Desulfovibrio、肠球菌属Enterococcus和螺杆菌属Helicobacter。
本发明还提供了所述的海洋益生元组合物在制备用于促进微生物发酵生产短链脂肪酸SCFAs的制剂中的应用。
进一步的,所述短链脂肪酸SCFAs包括乳酸、乙酸、丙酸、异丁酸、正丁酸、异戊酸和戊酸。
进一步的,所述海洋益生元组合物的用量为2‰(w/v)。
与现有技术相比,本发明的优点和有益效果是:
1、本发明以海洋低聚糖和海藻多酚作为有效活性成分制备得到了一种新的海洋益生元组合物,并首次验证了海藻多酚具有促进海洋低聚糖的功效。本发明的海洋益生元组合物能够显著促进多种肠道内或外源补充的益生菌增殖,并抑制多种肠道条件致病菌,从而起到调节人体肠道菌群、改善肠道功能,促进人体营养吸收的作用,且这些效果均明显优于单一低聚糖的作用,其组合配伍不仅合理有效,还克服了单一低聚糖作用的局限性。
2、本发明还首次验证了海洋益生元组合物可以显著促进肠道益生菌罗斯氏菌的增殖,以及抑制致病菌螺杆菌,并经微生物发酵产生多种有益于人体健康的SCFAs,尤其是戊酸。
3、本发明的海洋益生元组合物用量小,且作用效果佳,还具有原料来源丰富、结构特异、成本低、制备简单方便的优势,因此具有广泛的市场前景。
具体实施方式
以下通过实施例形式对本发明的上述内容再作进一步的详细说明。实施例中的实验方法,若未特别指明,实施例中的实验条件均为常规实验条件。实施例中所用的试验材料、试剂等,如无特殊说明,均可从商业途径得到。
实施例1
称取粉末状的褐藻低聚糖40g、红藻低聚糖50g和海藻多酚10g,混合均匀得到海洋益生元组合物。
实施例2
称取粉末状的红藻低聚糖45g、甲壳低聚糖45g和海藻多酚10g,混合均匀得到海洋益生元组合物。
实施例3
称取粉末状的褐藻低聚糖28g、红藻低聚糖42g、甲壳低聚糖20g和海藻多酚10g,混合均匀得到海洋益生元组合物。
实施例4
称取粉末状的褐藻低聚糖80g和海藻多酚20g,混合均匀得到海洋益生元组合物。
实施例5
称取粉末状的红藻低聚糖75g和海藻多酚25g,混合均匀得到海洋益生元组合物。
实施例6
称取粉末状的绿藻低聚糖78g和海藻多酚22g,混合均匀得到海洋益生元组合物。
实施例7:体外模拟人体肠道酵解试验
1、实验方法
(1)酵解培养基的制备:PYG培养基(采购于青岛高科技工业园海博生物技术有限公司)中添加0.02g/L氯高铁血红素、10μL/L维生素K1和1mg/L刃天青,调节pH至6.8,121℃灭菌15min,得到酵解培养基。
分别向酵解培养基中加入2‰的实施例1-6制备得到的海洋益生元组合物作为实验组;或者分别加入等量的甲壳低聚糖、褐藻低聚糖、红藻低聚糖、绿藻低聚糖、低聚木糖作为对比组1-5;以不添加任何试剂的酵解培养基作为空白对照组。
(2)肠道菌群稀释液的制备:收集连续3个月内饮食正常、无消化疾病、未服用任何抗生素的志愿者的新鲜粪便,将其等量混合后,立即储存于厌氧容器中,加入含0.5g/L半胱氨酸盐酸盐的无菌生理盐水,制取肠道菌群稀释液。
(3)肠道菌群发酵:分别将肠道菌群稀释液以5%的体积比接种到各组酵解培养基中,37℃厌氧培养48h后,离心,收集的上清液用来检测短链脂肪酸(SCFAs)的浓度,收集的沉淀物用来检测微生物多样性。
(4)短链脂肪酸浓度的检测:
采用GC-MS法,色谱柱:HP-INNO WAXMS(30mm×0.25μm,USA);进样口温度:230℃,载气:高纯氮气;流速:1.3mL/min。升温程序:起初温度100℃,保持0.5min后,柱温以每分钟5℃从100℃升至120℃,然后以每分钟2℃升至260℃;以一个扫描时间为0.2S,电子倍增压为500V的70eV电离能下记录质谱;进样体积1μL。
(5)微生物多样性的检测:将收集的沉淀物送至北京诺禾致源科技股份有限公司完成微生物多样性的检测。
2、检测结果
(1)微生物多样性的检测结果见表1。
表1:各实验组中主要有益菌和条件致病菌的相对丰度
注:*代表差异具有显著性(P<0.05),相对于空白组。
表1结果表明:与空白对照组相比,本发明实施例1-6制备的海洋益生元组合物和对比组的5种单一低聚糖均能有效促进肠道内益生菌罗斯氏菌(Roseburia cecicola)、鼠李糖乳杆菌(Lactobacillus rhamnosus)、嗜酸乳杆菌(Lactobacillus acidophilus)、弯曲乳酸杆菌(Lactobacillus curvatus)、动物双歧杆菌(Bifidobacterium animalis)、短双歧杆菌(Bifidobacterium breve)、长双歧杆菌(Bifidobacterium longum)的增殖,进而提高益生菌在人体肠道内的定植能力和数量。与此同时,与空白对照组相比,本发明实施例1-6制备的海洋益生元组合物和对比组的5种单一低聚糖能够显著抑制肠道内条件致病菌脱硫弧菌属(Desulfovibrio)、肠球菌属(Enterococcus)、螺杆菌属(Helicobacter),进而减少这些条件致病菌在人体肠道内的数量并避免它们的大量繁殖,由此降低由上述几种条件致病菌感染所引发的一系列人体疾病的概率,例如胃癌、慢性胃炎、消化道溃疡、尿路感染、腹部创伤感染等。并且,本发明的海洋益生元组合物对益生菌的促进作用和对条件致病菌的抑制作用均明显优于对比组单一的低聚糖的作用效果,且又以实施例3制备得到的海洋益生元组合物的效果最好。由此说明,本发明的海洋益生元组合物具有调节人体肠道内菌群结构的作用,通过同时增加益生菌和抑制病原菌来调节肠道菌群数量,改善肠道功能,促进营养吸收,从而维持人体健康。
除此之外,表1中还显示,与空白组相比,只有对比组1-3对乳酸乳球菌(Lactococcus lactis)的具有较弱的促进作用,但本发明实施例1-6制备的海洋益生元组合物却对乳酸乳球菌均具有明显的促进增殖的作用,且实施例3的海洋益生元组合物的效果最好。乳酸乳球菌是位于胃肠道中的益生菌,但其不属于人和动物的正常肠道菌群,因此不会定植于在口腔或胃肠道内,其对黏膜免疫和系统免疫的诱导具有积极的作用。而本发明的海洋益生元组合物增加了乳酸乳球菌的数量,说明了其不仅会改善肠道内本就定植的菌群的相对平衡,还能有效促进非定植的或外源补充的益生菌数量,使得内外益生菌群共同作用提高肠道功能。
(2)SCFAs浓度的检测结果如表2所示:
表2:各组酵解培养物的SCFAs浓度结果
注:*代表差异具有显著性(p<0.05),相对于空白组;“-”代表未检出。
表2结果表明,与空白组相比,本发明实施例1-6制备的海洋益生元组合物和对比组的5种单一低聚糖能够有效增加酵解培养物中乳酸、乙酸、丙酸、异丁酸、正丁酸和异戊酸的浓度,且本发明的海洋益生元组合物的作用效果明显优于对比组,其中以实施例3的海洋益生元组合物的效果最优。特别的,与空白组相比,本发明实施例1-6制备的海洋益生元组合物均通过酵解产生了较多的戊酸。
SCFAs通过肠道微生物发酵产生,不仅起到酸化肠道的作用,还可以调节多个系统的功能,如肠道、神经、内分泌和血液系统;SCFAs在维持肠道健康、预防和改善包括癌症在内的多种非传染性疾病方面发挥了重要作用。肠道中的SCFAs主要有乙酸、丙酸和丁酸等,其中乙酸随血液进入全身循环,能被大脑、心脏和外周组织氧化;丙酸被肝脏吸收,参与糖异生并抑制胆固醇合成;丁酸能够调节上皮细胞和免疫细胞的生长和凋亡,并对维持肠黏膜屏障完整性、稳定肠道微环境具有重要作用;戊酸可抑制艰难梭菌的生长。
综上说明,本发明的海洋益生元组合物不仅能够促进益生菌的增殖,还能够促进微生物发酵蛋白质、淀粉等营养物质来产生多种有益的SCFAs,增强肠道功能和机体健康,并且海藻多酚能够明显促进海洋低聚糖发挥益生元的作用。
以上实施例仅用以说明本发明的技术方案,而非对其进行限制;尽管参照前述实施例对本发明进行了详细的说明,对于本领域的普通技术人员来说,依然可以对前述实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或替换,并不使相应技术方案的本质脱离本发明所要求保护的技术方案的精神和范围。
Claims (10)
1.一种用于调节人体肠道菌群的海洋益生元组合物,其特征在于:包括海洋低聚糖和海藻多酚作为有效活性成分,所述海洋低聚糖和海藻多酚的质量比为3:1~9:1。
2.根据权利要求1所述的海洋益生元组合物,其特征在于,所述海洋低聚糖包括褐藻低聚糖、红藻低聚糖、绿藻低聚糖和甲壳低聚糖中的至少一种。
3.根据权利要求2所述的海洋益生元组合物,其特征在于,所述海洋益生元组合物具有下列组成之一:
(1)由褐藻低聚糖、红藻低聚糖和海藻多酚以4:5:1的质量比组成;
(2)由红藻低聚糖、甲壳低聚糖和海藻多酚以9:9:2的质量比组成;
(3)由褐藻低聚糖、红藻低聚糖、甲壳低聚糖和海藻多酚以14:21:10:5的质量比组成;
(4)由褐藻低聚糖和海藻多酚以4:1的质量比组成;
(5)由红藻低聚糖和海藻多酚以3:1的质量比组成;
(6)由绿藻低聚糖和海藻多酚以39:11的质量比组成。
4.权利要求1所述的海洋益生元组合物在制备用于调节人体肠道菌群和/或改善肠道功能的食品、保健品或药物制剂中的应用。
5.根据权利要求4所述的应用,其特征在于,所述海洋益生元组合物能够通过有效促进益生菌的增殖以及抑制条件致病菌,达到调节人体肠道菌群和/或改善肠道功能的作用。
6.根据权利要求5所述的应用,其特征在于,所述益生菌包括罗斯氏菌Roseburia cecicola、鼠李糖乳杆菌Lactobacillus rhamnosus、嗜酸乳杆菌Lactobacillus acidophilus、弯曲乳酸杆菌Lactobacillus curvatus、动物双歧杆菌Bifidobacterium animalis、短双歧杆菌Bifidobacterium breve、长双歧杆菌Bifidobacterium longum和乳酸乳球菌Lactococcus lactis。
7.根据权利要求5所述的应用,其特征在于,所述条件致病菌包括脱硫弧菌属Desulfovibrio、肠球菌属Enterococcus和螺杆菌属Helicobacter。
8.权利要求1所述的海洋益生元组合物在制备用于促进微生物发酵生产短链脂肪酸SCFAs的制剂中的应用。
9.根据权利要求8所述的应用,其特征在于,所述短链脂肪酸SCFAs包括乳酸、乙酸、丙酸、异丁酸、正丁酸、异戊酸和戊酸。
10.根据权利要求4所述的应用,或者权利要求8所述的应用,其特征在于,所述海洋益生元组合物的用量为2‰。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110617542.3A CN113397170B (zh) | 2021-06-02 | 2021-06-02 | 一种用于调节人体肠道菌群的海洋益生元组合物的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110617542.3A CN113397170B (zh) | 2021-06-02 | 2021-06-02 | 一种用于调节人体肠道菌群的海洋益生元组合物的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113397170A true CN113397170A (zh) | 2021-09-17 |
CN113397170B CN113397170B (zh) | 2023-02-24 |
Family
ID=77676022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110617542.3A Active CN113397170B (zh) | 2021-06-02 | 2021-06-02 | 一种用于调节人体肠道菌群的海洋益生元组合物的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113397170B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114259062A (zh) * | 2021-12-28 | 2022-04-01 | 浙江省农业科学院 | 高效调节肠道菌群的益生元组合物制备方法、设备及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1562071A (zh) * | 2004-04-16 | 2005-01-12 | 中国海洋大学 | 褐藻胶低聚糖作为益生元的应用 |
CN108440681A (zh) * | 2018-05-15 | 2018-08-24 | 中国海洋大学 | 一种绿藻硫酸多糖及其作为益生元在提高肠道有益菌增殖中的应用 |
US20200360447A1 (en) * | 2017-11-16 | 2020-11-19 | Korea University Research And Business Foundation | Method for producing marine algae-derived agarotriose, and use thereof as prebiotic |
CN112369608A (zh) * | 2019-12-27 | 2021-02-19 | 青岛博智汇力生物科技有限公司 | 一种含有海洋寡糖的减肥食品 |
-
2021
- 2021-06-02 CN CN202110617542.3A patent/CN113397170B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1562071A (zh) * | 2004-04-16 | 2005-01-12 | 中国海洋大学 | 褐藻胶低聚糖作为益生元的应用 |
US20200360447A1 (en) * | 2017-11-16 | 2020-11-19 | Korea University Research And Business Foundation | Method for producing marine algae-derived agarotriose, and use thereof as prebiotic |
CN108440681A (zh) * | 2018-05-15 | 2018-08-24 | 中国海洋大学 | 一种绿藻硫酸多糖及其作为益生元在提高肠道有益菌增殖中的应用 |
CN112369608A (zh) * | 2019-12-27 | 2021-02-19 | 青岛博智汇力生物科技有限公司 | 一种含有海洋寡糖的减肥食品 |
Non-Patent Citations (3)
Title |
---|
刘太浩等: "海藻多酚对动物肠道中有益菌(双歧杆菌 DM8504 菌株为例)增殖及肠道菌群失调动物模型的恢复的影响作用", 《科学技术成果》, 30 December 2007 (2007-12-30) * |
杨会成等: "海藻中多酚类化学成分及其生物活性研究进展", 《中国海洋药物杂志》, no. 5, 31 October 2007 (2007-10-31), pages 53 - 39 * |
林丽云等: "海洋生物新材料中益生元的开发与应用", 《现代食品科技》, no. 4, 31 December 2005 (2005-12-31), pages 115 - 117 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114259062A (zh) * | 2021-12-28 | 2022-04-01 | 浙江省农业科学院 | 高效调节肠道菌群的益生元组合物制备方法、设备及应用 |
CN114259062B (zh) * | 2021-12-28 | 2023-12-22 | 浙江省农业科学院 | 高效调节肠道菌群的益生元组合物制备方法、设备及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113397170B (zh) | 2023-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102191202B (zh) | 一种乳酸菌的高密度培养方法 | |
CN101366734A (zh) | 合生素药物组合物 | |
CN103283975A (zh) | 一种用喷雾干燥制备益生菌微胶囊的方法 | |
CN108782758B (zh) | 一种发酵型合生元羊奶粉及其制备方法 | |
CN114854643A (zh) | 一种促进乳杆菌和双歧杆菌协同增殖的培养基及其应用 | |
CN110521939A (zh) | 一种调节肠道健康的益生菌发酵食品及其制备方法 | |
CN109929779A (zh) | 一种含有生物活性肽的益生菌制剂及其制备方法和应用 | |
CN105567669A (zh) | 益生菌微胶囊制剂及其制备方法 | |
CN109593666A (zh) | 一种复合微生态制剂及其制备方法和应用 | |
CN102524794B (zh) | 一种降血清胆固醇马克斯克鲁维酵母冻干菌粉的制备方法 | |
CN106635912A (zh) | 复合乳酸菌的联合发酵工艺 | |
CN111254088A (zh) | 一种凝结芽孢杆菌菌株及其应用 | |
CN116676225A (zh) | 一株具有安神助眠功效的鼠李糖乳杆菌lr-28菌株、发酵产物、嘉眠菌群组合剂及应用 | |
CN115851535A (zh) | 具有调节免疫力作用的鼠李糖乳酪杆菌wfp52及应用 | |
CN105475988A (zh) | 一种混合型肠道微生态制剂及其制备方法 | |
CN113397170B (zh) | 一种用于调节人体肠道菌群的海洋益生元组合物的应用 | |
CN111228316B (zh) | 用于改善糖尿病的复合益生菌 | |
CN106617095B (zh) | 一种阿胶益生菌口服液及其制备方法 | |
CN117106673A (zh) | 一种双歧杆菌增菌剂及在高密度发酵中的应用 | |
CN1928073A (zh) | 酪酸菌加嗜酸乳杆菌联合发酵工艺 | |
CN117327616A (zh) | Lactiplantibacillus plantarum ZN1及其应用 | |
CN112042748A (zh) | 一种适用于中老年人群的牦牛乳益生菌粉及其制备工艺 | |
CN114984065B (zh) | 一种提高免疫力的益生菌组合物及其制备方法 | |
CN107929329B (zh) | 一种消栓降脂益生复合菌中药颗粒及其制备方法 | |
CN112438404B (zh) | 一种黄参多糖的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |